Scleroderma-Related Raynaud’s Phenomenon Treated with Alprostadil

Author: Maureen Newman
Date Published: January-2015
Source: Scleroderma News

Important to the development of any treatment for scleroderma is a clinical study investigating the pharmacodynamics and pharmacokinetics of a potential drug candidate. NexMed (USA), Inc., a subsidiary of Apricus Biosciences, Inc., is sponsoring a currently enrolling clinical trial investigating these two aspects of alprostadil in systemic sclerosis (SSc) patients with a secondary diagnosis of Raynaud’s phenomenon, also known as scleroderma-related Raynaud’s phenomenon.